Synthesis and preclinical evaluation of an 18 F labeled PDE7 inhibitor for PET neuroimaging
- 1 December 2015
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 42 (12) , 975-981
Abstract
No abstract availableKeywords
Funding Information
- FWO (1211313N, 1508215N)
- University of Antwerp, Belgium (KP 2013)
- Antwerp University Hospital, Belgium
This publication has 25 references indexed in Scilit:
- Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target EngagementACS Medicinal Chemistry Letters, 2014
- Highly Potent, Selective, and Orally Active Phosphodiesterase 10A InhibitorsJournal of Medicinal Chemistry, 2011
- Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissuesNeuropharmacology, 2010
- Beneficial effects of rolipram in the R6/2 mouse model of Huntington's diseaseNeurobiology of Disease, 2008
- Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical UsePharmacological Reviews, 2006
- Improving Memory: A Role for PhosphodiesterasesCurrent Pharmaceutical Design, 2006
- Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: Comparison with rolipramBrain Research, 2006
- The Crystal Structure of AMP-Bound PDE4 Suggests a Mechanism for Phosphodiesterase Catalysis,Biochemistry, 2003
- Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitorsTrends in Pharmacological Sciences, 1990
- Selective inhibition of one of the cyclic AMP phosphodiesterases from rat brain by the neurotropic compound rolipramBiochemical Pharmacology, 1985